NAII · XBRL financial data

Natural Alternatives International financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NAII's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cost of goods and services sold	148,078	140,457	135,857	106,931	120,571	133,518
Gross profit	30,442	30,509	18,158	6,865	9,289	8,997
Research and development	1,900	2,500	2,100	1,900	1,800	2,300
Operating income (loss)	13,672	13,679	4,713	(8,534)	(8,660)	(18,752)
Interest income	1	0	33	176	168	50
Other income (expense)	(21)	(55)	(82)	(93)	7	(61)
Income tax expense (benefit)	1,357	2,947	1,033	(2,247)	2,835	430
Net income (loss)	10,768	10,712	2,522	(7,217)	(13,575)	(20,695)
Earnings per share, basic USD per share	1.71	1.75	0.43	(1.23)	(2.28)	(3.43)
Earnings per share, diluted USD per share	1.69	1.74	0.43	(1.23)	(2.28)	(3.43)
Weighted average shares, basic thousands of shares	6,291	6,117	5,863	5,871	5,947	6,028
Weighted average shares, diluted thousands of shares	6,379	6,155	5,878	5,871	5,947	6,028

Fiscal years (NAII's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	32,133	21,833	13,604	11,981	12,325	7,388
Accounts receivable	17,946	17,422	7,022	16,891	14,644	20,650
Inventory	27,006	32,475	29,694	24,249	24,871	30,753
Prepaid and other current assets	2,168	1,805	5,995	7,997	6,792	2,580
Total current assets	80,348	76,746	57,010	61,610	59,276	65,434
Property and equipment, net	22,271	44,573	53,841	52,211	50,890	35,605
Right-of-use asset	15,877	21,701	20,369	43,537	41,054	24,062
Total assets	120,281	146,003	134,152	162,342	151,939	126,446
Accounts payable	11,893	16,185	7,778	12,740	15,352	18,146
Accrued liabilities	2,441	2,787	2,409	2,847	3,105	4,601
Total current liabilities	22,072	23,261	15,884	23,465	28,804	37,717
Lease liability, non-current	16,481	22,047	18,965	46,468	45,970	28,564
Total liabilities	40,198	57,483	45,380	79,747	83,513	76,487
Retained earnings	66,949	77,661	80,183	72,966	59,391	38,696
Total stockholders' equity	80,083	88,520	88,772	82,595	68,426	49,959
Total liabilities and equity	120,281	146,003	134,152	162,342	151,939	126,446
Common shares outstanding (cover page) thousands of shares	6,435	6,090	6,089	6,199	6,177	22,113

Fiscal years (NAII's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	10,768	10,712	2,522	(7,217)	(13,575)	(20,695)
Stock-based compensation	1,430	968	1,015	1,200	977	603
Depreciation and amortization	4,338	4,165	4,250	4,647	4,560	4,709
Net cash from operating activities	20,806	11,866	7,019	(1,497)	5,932	(8,916)
Purchases of property and equipment	5,107	26,488	13,524	3,017	3,614	3,701
Net cash from investing activities	(5,039)	(26,458)	(13,467)	(3,017)	(3,614)	(3,701)
Share repurchases	4,147	5,503	1,503	221	178	89
Proceeds from long-term debt	0	10,000	0	—	0	11,000
Repayments of long-term debt	0	205	278	288	296	8,994
Net cash from financing activities	(14,112)	4,292	(1,781)	2,891	(1,974)	7,766
Net change in cash	1,655	(10,300)	(8,229)	(1,623)	344	(4,851)

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Natural Alternatives International	7,388	not reported	(1,066)*	22.1M	6.9 quarters	Q4 FY26 10-KJun 30, 2026
PharmaCyte Biotech	17,739	0	(781)	10.7M	22.8 quarters	Q1 FY27 10-QJul 31, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Adial Pharmaceuticals	28,712	not reported	(6,363)*	2.6M	4.5 quarters	Q2 FY26 10-Q/AJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
Adia Nutrition	128	485	(109)*	94.4M	1.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.